Clinical Trials Logo

Ureteral Stent clinical trials

View clinical trials related to Ureteral Stent.

Filter by:
  • None
  • Page 1

NCT ID: NCT06045962 Enrolling by invitation - Ureteral Stent Clinical Trials

Optimal Stent Duration After Ureteroscopy

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how soon ureteral stents can be safely removed following surgery.

NCT ID: NCT05738304 Recruiting - Kidney Stone Clinical Trials

Ureteral Stenting After Retrograde Intrarenal Surgery for Renal Stones

Start date: January 12, 2021
Phase: N/A
Study type: Interventional

Several studies evaluated the benefit of a short-term external ureteral catheter (UC) compared to double-J (DJ) ureteral stent after flexible ureteroscopy (URS); the results were controversial. These studies had combined analyses of ureteral and renal stones with a high risk of selection bias. Studies comparing external UC and DJ stent after flexible URS for isolated renal stones are lacking. In the present study, the investigators will compare the outcomes of using a one-day external UC versus a DJ internal ureteral stent for ureteral drainage after retrograde flexible URS (retrograde intrarenal surgery "RIRS") for renal stones. The investigators aim to identify the best ureteral drainage method after RIRS regarding stone clearance, complications, and stent-related symptoms.

NCT ID: NCT04829461 Completed - Cystoscopy Clinical Trials

Effectiveness of Ambu® aScope™ 4 Cysto With the aView™ 2 Advance for Flexible Cystoscopy

Start date: April 27, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the use of the single-use Ambu® aScope™ 4 Cysto for removal of ureteral stents as compared to routine flexible reusable cystoscopes.

NCT ID: NCT04325880 Recruiting - Ureteral Stent Clinical Trials

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Start date: December 1, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of this prospective, single-centre randomized controlled trial is to assess the efficacy of three different drugs in treatment of ureteral stents related symptoms (Beta 3 adrenergic receptor agonist; Mirabegron 50mg) vs. (Alpha 1 adrenergic receptor antagonist; Tamsulosin 0.4mg) vs. (Anticholinergic; Solifenacin 10 mg) using validated symptoms questionnaires. In addition, adverse events of the utilized medications will be monitored during study period as a secondary objective.